Advertisement
Screener

Personalis, Inc. (PSNL) Current Ratio

Personalis, Inc. (PSNL) Current Ratio

  • Current ratio · latest quarter: Value 5.28×; Formula and calculation Current assets / current liabilities..

Current ratio

Overview →

Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.

MetricValueFormula and calculation
Current ratio · latest quarter5.28×Current assets / current liabilities.

$245.05M ÷ $46.38M ≈ 5.28×

Calculation inputs

InputAmount with unitRaw financial data
Current assets245.05M USDAssets, Current
Current obligations46.38M USDLiabilities, Current
Cash and equivalents93.97M USDCash and Cash Equivalents, at Carrying Value
Short-term securities(m)
Customer receivables15.10M USDAccounts Receivable, after Allowance for Credit Loss, Current
Inventory(m)
Payables16.00M USDAccounts Payable, Current
Borrowing debt due within one year(m)Long-term Debt, Current Maturities

Calculated history

Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.

Period endingCurrent assets (USD)Current obligations (USD)Cash and equivalents (USD)Short-term securities (USD)Customer receivables (USD)Inventory (USD)Payables (USD)Borrowing debt due within one year (USD)Current ratio
2026-06-30$245.05M$46.38M$93.97M(m)$15.10M(m)$16.00M(m)5.28×
2026-03-31$258.20M$39.05M$73.59M(m)$13.02M(m)$12.68M(m)6.61×
2025-12-31$267.95M$39.63M$124.25M(m)$16.20M(m)$12.99M(m)6.76×
2025-09-30$174.40M$36.16M$49.97M(m)$14.38M(m)$11.15M(m)4.82×
2025-06-30$193.34M$31.72M$53.37M(m)$9.95M(m)$9.93M(m)6.09×
2025-03-31$206.42M$29.89M$71.00M(m)$10.97M(m)$7.91M(m)6.91×
2024-12-31$203.01M$31.13M$91.42M(m)$8.14M(m)$6.40M(m)6.52×
2024-09-30$170.28M$36.41M$75.80M(m)$13.47M(m)$12.45M(m)4.68×
2024-06-30$113.10M$34.13M$47.75M(m)$12.92M(m)$9.94M(m)3.31×
2024-03-31$120.44M$31.37M$43.98M(m)$11.35M(m)$9.18M(m)3.84×
2023-12-31$146.74M$47.23M$56.98M(m)$17.73M(m)$14.92M(m)3.11×
2023-09-30$148.22M$32.48M$72.19M(m)$13.67M(m)$8.96M(m)4.56×
2023-06-30$160.96M$28.59M$97.19M(m)$10.13M(m)$8.85M(m)5.63×
2023-03-31$182.77M$34.14M$87.17M(m)$18.10M(m)$10.93M(m)5.35×
2022-12-31$199.70M$33.13M$89.13M(m)$16.64M(m)$12.85M(m)6.03×
2022-09-30$221.91M$33.74M$83.52M(m)$13.59M(m)$10.78M(m)6.58×
2022-06-30$260.04M$41.51M$86.73M(m)$12.88M(m)$21.39M(m)6.27×
2022-03-31$294.03M$39.84M$91.59M(m)$13.52M(m)$12.28M(m)7.38×
2021-12-31$318.23M$31.31M$105.58M(m)$18.47M(m)$9.22M(m)10.16×
2021-09-30$329.01M$26.52M$79.57M(m)$10.53M(m)$7.29M(m)12.41×
2021-06-30$354.31M$34.09M$70.08M(m)$9.28M(m)$8.92M(m)10.39×
2021-03-31$372.67M$38.56M$137.09M(m)$8.05M(m)$6.52M(m)9.66×
2020-12-31$220.72M$40.64M$68.53M(m)$6.35M(m)$8.30M(m)5.43×
2020-09-30$223.59M$35.90M$133.25M(m)$5.90M(m)$6.51M(m)6.23×
2020-06-30$120.12M$43.04M$25.04M(m)$5.38M(m)$7.49M(m)2.79×
2020-03-31$135.42M$52.12M$46.69M(m)$5.51M(m)$10.34M(m)2.60×
2019-12-31$139.58M$49.96M$55.05M(m)$3.30M(m)$7.34M(m)2.79×
2019-09-30$140.30M$47.39M$87.01M(m)$4.45M(m)$7.76M(m)2.96×
2019-06-30$176.17M$56.34M$163.27M(m)$7.46M(m)$8.78M$1.02M3.13×
2018-12-31$29.56M$57.85M$19.74M(m)$4.46M(m)$6.57M$5.00M0.51×

(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.

Similar stocks

Stock NameCountryMarket CapPE Ratio
Fortrea Holdings Inc. (FTRE)United States$1.903B-19.43
CASTLE BIOSCIENCES INC (CSTL)United States$1.074B-37.45
Lumexa Imaging Holdings, Inc. (LMRI)United States$0.951B
Fulgent Genetics, Inc. (FLGT)United States$0.593B-6.70
CareDx, Inc. (CDNA)United States$3.174B13.21
BIODESIX INC (BDSX)United States$0.312B
EXAGEN INC. (XGN)United States$0.212B-5.95
Freenome, Inc. (FRNM)United States$0.143B
SERA PROGNOSTICS, INC. (SERA)United States$0.062B-5.75
AMERICAN SHARED HOSPITAL SERVICES (AMS)United States$0.010B-5.64